Revolutionizing dry eye care with shorter-duration cryopreserved amniotic membrane therapy
Damon Dierker, OD, FAAO, shares latest updates in research on sutureless cryopreserved amniotic membrane for moderate-to-severe dry eye with short treatment duration.
In this illuminating interview, Damon Dierker, OD, FAAO, discusses the groundbreaking potential of sutureless cryopreserved amniotic membrane therapy for moderate to severe dry eye.
Dierker, a prominent expert in the field, highlights findings from the DREAM study, showcasing the remarkable durability and efficacy of a single placement for up to three months. Notably, he reveals compelling data indicating that a shorter treatment duration of just 2 days can yield equivalent benefits, reshaping clinical recommendations and enhancing patient convenience.
As the conversation unfolds, Dierker foresees a transformative impact in 2024, with regenerative therapy playing a crucial role in addressing conditions like Neurotrophic Keratitis and persistent corneal staining.
